Immix Biopharma (NASDAQ:IMMX) Shares Up 1.5% - Here's What Happened

Shares of Immix Biopharma, Inc. (NASDAQ:IMMX - Get Free Report) traded up 1.5% on Tuesday . The stock traded as high as $2.71 and last traded at $2.66. 144,413 shares were traded during mid-day trading, a decline of 5% from the average session volume of 151,846 shares. The stock had previously closed at $2.62.

Analyst Ratings Changes

IMMX has been the topic of several recent analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $7.00 price objective on shares of Immix Biopharma in a research report on Wednesday, June 4th. Wall Street Zen upgraded shares of Immix Biopharma to a "hold" rating in a report on Friday, June 27th.

Immix Biopharma Stock Performance

The company's 50-day moving average price is $2.24 and its 200 day moving average price is $1.99. The stock has a market cap of $75.55 million, a PE ratio of -3.87 and a beta of 0.24.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Immix Biopharma stock. Jane Street Group LLC bought a new position in Immix Biopharma, Inc. (NASDAQ:IMMX - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 17,523 shares of the company's stock, valued at approximately $39,000. Jane Street Group LLC owned approximately 0.06% of Immix Biopharma at the end of the most recent quarter. Institutional investors own 11.26% of the company's stock.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.